Efficacy and safety of Apixaban for the prevention of thrombosis in arteriovenous grafts
Authors:
- Arash HedayatAHArash Hedayat
- Aidin Esrafilian SoltaniASAidin Esrafilian Soltani
- Mahdi HakiminezhadMHMahdi Hakiminezhad
- Fateme ZareianFZFateme Zareian
- Mandana SaneianMSMandana Saneian
- Mohamad MoradmandMMMohamad Moradmand
- Sahand AbrishamiSASahand Abrishami
- Mohamad Hosein Tabatabaei NodoushanMNMohamad Hosein Tabatabaei Nodoushan
- Ali PouriayevaliAPAli Pouriayevali
- Mahdi MohebbiMMMahdi Mohebbi
- Helia GhorbaniHGHelia Ghorbani
Open Access
- 15 January 2024
- journal article
- research article
- Published by PAGEPress Publications in European Journal of Translational Myology
- Vol. 34 (1)
Abstract
This research aims to fill a vital gap in existing studies by evaluating the efficacy and safety of Apixaban, a direct oral anticoagulant, in the prevention of arteriovenous graft (AVG) thrombosis, thereby offering substantial insights into alternative anticoagulant options for hemodialysis patients. Conducted as a multi-center, randomized, double-blind, placebo-controlled trial, this study involved end-stage renal disease (ESRD) patients who had recently received polytetrafluoroethylene grafts. Participants were assigned to receive either Apixaban at a dose of 2.5 mg twice daily or a placebo. The primary outcome measure was the occurrence of graft thrombosis, while secondary outcomes focused on the incidence and severity of bleeding. Analytical methods included Kaplan-Meier estimates, Cox proportional hazards models, and conventional statistical tests. With 96 patients enrolled, the study found that Apixaban significantly reduced the incidence of AVG thrombosis compared to placebo (16.7% vs. 62.5%, P < 0.0001). Notably, this reduction in thrombosis incidence was not accompanied by an increase in bleeding events, thus affirming the safety profile of Apixaban as established in prior research. Apixaban is identified as an efficacious alternative to traditional anticoagulants in the prevention of AVG thrombosis among hemodialysis patients, representing a notable advancement in the care of individuals with ESRD. The results of this study support further investigations into the optimal dosing strategies specifically tailored for this patient demographic.Keywords
This publication has 26 references indexed in Scilit:
- Effect of Fish Oil Supplementation on Graft Patency and Cardiovascular Events Among Patients With New Synthetic Arteriovenous Hemodialysis GraftsJAMA, 2012
- Chronic Kidney Disease and End-Stage Renal Disease Predict Higher Risk of Mortality in Patients with Primary Upper Gastrointestinal BleedingAmerican Journal of Nephrology, 2012
- Current Management of Vascular AccessClinical Journal of the American Society of Nephrology, 2007
- Uremic bleeding: Pathophysiology and clinical risk factorsThrombosis Research, 2006
- Randomized Trial of Folic Acid for Prevention of Cardiovascular Events in End-Stage Renal DiseaseJournal of the American Society of Nephrology, 2004
- Randomized Controlled Trial of Clopidogrel plus Aspirin to Prevent Hemodialysis Access Graft ThrombosisJournal of the American Society of Nephrology, 2003
- Low-Intensity Warfarin Is Ineffective for the Prevention of PTFE Graft Failure in Patients on HemodialysisJournal of the American Society of Nephrology, 2002
- Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty.Radiology, 1995
- Defective platelet aggregation in uremia is transiently worsened by hemodialysisAmerican Journal of Kidney Diseases, 1995
- Pathogenesis of Venous ThrombosisChest, 1992